PL2001456T3 - Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych - Google Patents

Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych

Info

Publication number
PL2001456T3
PL2001456T3 PL07727719T PL07727719T PL2001456T3 PL 2001456 T3 PL2001456 T3 PL 2001456T3 PL 07727719 T PL07727719 T PL 07727719T PL 07727719 T PL07727719 T PL 07727719T PL 2001456 T3 PL2001456 T3 PL 2001456T3
Authority
PL
Poland
Prior art keywords
treatment
opioid receptor
receptor antagonist
kappa opioid
containing compositions
Prior art date
Application number
PL07727719T
Other languages
English (en)
Inventor
Lars-Holger Hermann
Original Assignee
Emodys Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006015733A external-priority patent/DE102006015733A1/de
Priority claimed from DE102006016991A external-priority patent/DE102006016991A1/de
Application filed by Emodys Gmbh filed Critical Emodys Gmbh
Publication of PL2001456T3 publication Critical patent/PL2001456T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL07727719T 2006-04-04 2007-04-03 Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych PL2001456T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102006015733A DE102006015733A1 (de) 2006-04-04 2006-04-04 Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit
DE102006016991A DE102006016991A1 (de) 2006-04-11 2006-04-11 Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen
EP07727719A EP2001456B1 (de) 2006-04-04 2007-04-03 Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
PCT/EP2007/053248 WO2007115975A2 (de) 2006-04-04 2007-04-03 Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen

Publications (1)

Publication Number Publication Date
PL2001456T3 true PL2001456T3 (pl) 2010-05-31

Family

ID=38110094

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07727719T PL2001456T3 (pl) 2006-04-04 2007-04-03 Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych

Country Status (17)

Country Link
US (1) US8063059B2 (pl)
EP (1) EP2001456B1 (pl)
JP (1) JP5128578B2 (pl)
AT (1) ATE450256T1 (pl)
AU (1) AU2007236003B2 (pl)
CA (1) CA2646899C (pl)
CY (1) CY1109862T1 (pl)
DE (1) DE502007002185D1 (pl)
DK (1) DK2001456T3 (pl)
EA (1) EA014820B1 (pl)
ES (1) ES2337622T3 (pl)
HR (1) HRP20100113T1 (pl)
PL (1) PL2001456T3 (pl)
PT (1) PT2001456E (pl)
RS (1) RS51211B (pl)
SI (1) SI2001456T1 (pl)
WO (1) WO2007115975A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY163014A (en) 2008-01-22 2017-07-31 Lilly Co Eli Kappa selective opioid receptor antogonist
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
JP6448645B2 (ja) * 2013-12-20 2019-01-09 ハー・ルンドベック・アクチエゼルスカベット メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用
PL3137081T3 (pl) 2014-04-28 2018-06-29 Orphomed, Inc. Dimer buprenorfiny i jego zastosowanie w leczeniu chorób układu pokarmowego
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) * 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
US6242456B1 (en) * 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
WO2002013759A2 (en) * 2000-08-15 2002-02-21 Cpd Llc Method of treating the syndrome of type 2 diabetes in humans
US20020045572A1 (en) * 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
WO2002049643A1 (en) * 2000-12-21 2002-06-27 The Mclean Hospital Corporation Treatment of depression
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
CA2521396A1 (en) * 2003-04-04 2004-10-21 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
JP2007526328A (ja) 2004-03-02 2007-09-13 ファルマシア コーポレーション 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物
PT1758596E (pt) * 2004-05-26 2010-06-23 Inotek Pharmaceuticals Corp Derivados de purina como agonistas do receptor de adenosina a1 e processos para a sua utilização
WO2005117838A1 (en) * 2004-06-02 2005-12-15 Galephar M/F Stable oral pharmaceutical compositions of buprenorphine and derivatives

Also Published As

Publication number Publication date
EA200802104A1 (ru) 2009-04-28
SI2001456T1 (sl) 2010-04-30
JP2009532434A (ja) 2009-09-10
ATE450256T1 (de) 2009-12-15
CY1109862T1 (el) 2014-09-10
WO2007115975A2 (de) 2007-10-18
EP2001456B1 (de) 2009-12-02
AU2007236003A1 (en) 2007-10-18
US8063059B2 (en) 2011-11-22
WO2007115975A3 (de) 2008-02-14
CA2646899C (en) 2014-05-06
ES2337622T3 (es) 2010-04-27
EA014820B1 (ru) 2011-02-28
US20090181999A1 (en) 2009-07-16
CA2646899A1 (en) 2007-10-18
JP5128578B2 (ja) 2013-01-23
PT2001456E (pt) 2010-03-03
AU2007236003B2 (en) 2012-10-18
RS51211B (sr) 2010-12-31
EP2001456A2 (de) 2008-12-17
HRP20100113T1 (hr) 2010-04-30
DK2001456T3 (da) 2010-04-12
DE502007002185D1 (de) 2010-01-14

Similar Documents

Publication Publication Date Title
IL208895A0 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
TN2011000171A1 (en) Isonicotinamide orexin receptor antagonists
SI1729753T1 (sl) Uporaba antagonistov NMDA receptorjev za zdravljenje tinitusa povzročenega s kohlearno eksitotoksičnostjo
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
NZ594140A (en) C5ar antagonists
EP2215049A4 (en) P2X3 RECEPTOR ANTAGONISTS USED IN THE TREATMENT OF PAIN
HK1134084A1 (en) Pyridyl piperidine orexin receptor antagonists
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
HK1120442A1 (en) Novel opioid antagonists
IL187966A0 (en) New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
PL2001876T3 (pl) Związki 8-azabicyklo/3.2.1/oktanu jako antagoniści receptora opioidowego mu
RS20090208A (en) Pyrazoline compounds as mineralocorticoid receptor antagonists
EP1899318A4 (en) NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF STOMACH DARM DISEASES
SI2238110T1 (sl) Derivati 5,6-bisaril-2-piridin-karboksamida, njihova priprava in njihova terapevtska uporaba kot antagonisti receptorjev urotenzina II
HK1094674A1 (en) Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases cb1
SI2001456T1 (sl) Uporaba zmesi, ki vsebuje antagonist na opioidnem kapa receptorju za zdravljenje disocialnih bolezni
HK1135110A1 (en) Nk1 receptor antagonist composition nk1
ZA200900613B (en) 4-arylalkoxymethyl-4-phenyl piperidines and their use as neurokinin receptor antagonist for the treatment of CNS disorders
HK1102303A1 (en) Synthesis of ccr5 receptor antagonists ccr5
MX2009006313A (es) Antagonistas v3 para el tratamiento o prevencion de dolor cronico.